- Research Article
- 10.1182/blood.2025028645
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.
- Mar 19, 2026
- Blood
- Stefan N Constantinescu + 2 more +2
Publications from 2021 to 2026
Showing 10 of 381 papers
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.
Clostridioides difficile infection surveillance in Belgium: trends and insights from 2013 to 2024.
Pyrogenic reactions in haemodialysis patients linked to contaminated citrate lock.
Clinical Outcomes and Management in Late Diagnosed Siblings Affected With Attenuated GSD Ib.
Glycogen storage disease 1b (GSD1b) typically presents in early infancy with poor fasting tolerance, hepatomegaly, and neutropenia. We report two siblings who were diagnosed with GSD1b in adulthood. Both had a normal fasting tolerance throughout childhood and, as adults, were able to fast for at least 16 h without developing hypoglycaemia. The older sibling developed nodular cirrhosis during adolescence. The younger sibling exhibited a more pronounced metabolic phenotype, including hyperuricaemia leading to recurrent gout and nephrolithiasis. He experienced occasional episodes of mild neutropenia that were corrected with empagliflozin treatment. To our knowledge, these represent the first reported patients with GSD1b presenting in adulthood with non-hypoglycaemic complications of the disease and without overt neutropenia or neutrophil dysfunction.
Read moreSuccinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.
Despite intriguing roles for the Succinate receptor (Sucnr1) in inflammation, few studies have explored its role in hematopoiesis. Here, we show that low SUCNR1 represents a marker for reduced overall and progression-free survival in acute myeloid leukemia (AML) patients. Succinic acid, which displays Sucnr1-dependent and independent effects, promotes disease in mouse models of pre-leukemic myelopoiesis, AML and AML xenografts, expressing low SUCNR1. In vivo global or hematopoietic deletion of Sucnr1 induces expansion of hematopoietic stem and progenitor cells (HSPC) and hematopoiesis, whilst Sucnr1-tomato+ HSPC display restricted engraftment potential. Mechanistically, activation of Sucnr1 counterbalances the stimulatory effect of intracellular succinate in HSPC and preserves HSPC transcriptional programs via control of S100a8/S100a9. Blocking S100a9 with tasquinimod rescues the defects of Sucnr1 knock-out mice, and combined with a potent Sucnr1 agonist shows therapeutic value in AML mice. In AML xenografts, single-cell RNA-sequencing reanalyses confirm SUCNR1 as a therapeutic vulnerability in patients. Together, Sucnr1 signaling restricts hematopoiesis at least partially through HSPC and via control of S100a8/S100a9. Its dysregulation emerges as contributor to malignancy that opens therapeutic avenues for AML patients.
Read morePrecision medicine and the chaos theory in rheumatoid arthritis.
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.
Bladder carcinomas are immunogenic, and patients with bladder cancer benefit from immune checkpoint therapy. This is correlated to a high tumor mutation burden, which provides a higher number of neoepitopes that can be recognized by tumor-specific CD8+ T cells. Intravesical Bacillus Calmette-Guérin (BCG) is used to treat non-muscle invasive bladder cancer (NMIBC), but its mechanism of action remains elusive. Most lymphocytes appearing in the urine of BCG-treated patients are CD4+ T cells though preclinical studies showed that CD8+ T cells are also necessary for BCG treatment efficacy. It is currently unknown which proportion of patients with non-metastatic bladder cancer develop a spontaneous antitumor CD8+ response, and if BCG treatment influences this response. In a first cohort of 15 NMIBC and 9 muscle invasive bladder cancer patients, we used IFN-y ELISPOT assays to screen for the presence of anti-neoepitope CD8+ T cells in the blood, tumor and urine. In a second cohort of 4 NMIBC patients, we analyzed the features and specificity of CD8+ T cells infiltrating the tumoral or bladder tissues before and after BCG using single cell transcriptomic analyses. A total of 31 tumor-infiltrating CD8+ clonotypes were screened against neoepitopes and tumor cDNA libraries. 9 out of 24 patients from the first cohort mounted a spontaneous and functional anti-neoepitope T-cell response in blood and/or tumor. In 5 patients from this cohort who were treated with BCG, no neoantigen-specific T cells were detected in urine during treatment. In the second cohort, 6 out of 6 TCRs from exhausted CD8+ TILs from one patient recognized 5 different neoepitopes. T-cell receptor (TCR) repertoire analyses indicated that the frequencies of these tumor-specific T cells did not increase after BCG instillations, neither in the bladder nor in the blood. None of the 25 other TCRs of CD8+ T cells recognized tumor-specific antigens. We show that one third of patients with non-metastatic bladder cancer mount a spontaneous and functional anti-neoepitope CD8+ T-cell response detectable in blood or tumor. In 4 patients with NMIBC, BCG treatment did not boost or induce the anti-neoepitope response, suggesting alternative mechanisms of action for its efficacy.
Read moreBuilding a transparent and functional laboratory culture: guidelines for creating a Laboratory Handbook for principal investigators.
3113 – PROTEIN S-ACYLATION DYNAMICS PROVIDE METABOLIC FLEXIBILITY TO ACUTE MYELOID LEUKEMIA CELLS
#2175 An expanded proteomic workflow using data-independent acquisition mass spectrometry for the identification of target antigens in membranous nephropathy
Abstract Background and Aims In recent years, an innovative strategy using laser microdissection and mass spectrometry (LCM/MS) markedly expanded the landscape of antigens associated with membranous nephropathy (MN). Specific associations with phenotypes, diseases and sometimes reversible triggers led to a novel antigen-based classification of MN, paving the way for precision medicine and stressing the need for more routine use of proteomics in MN. Method In this work, we expanded the original technique of LCM/MS by integrating the more comprehensive data-independent acquisition (DIA) approach. Compared to conventional data-dependent acquisition (DDA), DIA MS enables the identification and quantification of every detectable peptide in a sample. It is also more reproducible, especially for low-abundance species. Computational analysis tools, including principal component analysis and differential abundance analyses, were then used to analyze and compare protein abundances. Results First, as a validation of our pipeline, we confirmed the significant enrichment in PLA2R, IgG4 and complement proteins and provided molecular evidence for complement activation in glomeruli from patients with PLA2R-MN. Next, we showed that, compared to conventional DDA, DIA increased the number of glomerular proteins (∼3800 vs ∼1200) identified in healthy glomeruli; allowed the detection of all known antigens except NELL1 in normal glomeruli; and increased the detection rate of antigens from 46% to 83% in PLA2R-negative MN. Out of 23 PLA2R-negative MN cases, with a non-significant staining for PLA2R on immunohistochemistry, our proteomic workflow identified NELL1 in seven (30%); THSD7A in three (13%); PLA2R in three (13%); NCAM1 in two (9%); PCSK6 in two (9%); CNTN1 in one (4%) and NDNF in one (4%). Confocal microscopy confirmed the suspected target antigens in immune deposits along glomerular basement membranes. Reverse phenotyping showed that three out of the seven cases of NELL1-MN were associated with malignancies; the two patients with NCAM1-MN had mixed connective tissue disease; one of the three patients with THSD7A-MN had neuroendocrine malignancy; the patient with NDNF-MN had syphilis; and one patient with PCSK6-MN had systemic sclerosis. Conclusion An integrative approach combining LCM and DIA MS is a powerful tool to identify target antigens and unravel disease mechanisms in MN.
Read more